Cicco-Ligandrol LGD4033 5mg

Cicco-Ligandrol LGD4033 5mg

Cicco-Ligandrol LGD4033 5mg 


Cicco-Ligandrol LGD4033 5mg  is a Selective Androgen Receptor Modulators (SARMs). NOT FOR USE by children, teenagers and pregnant or nursing women. Fully developed men and women over 21 years of age, can use SARMs.

Although SARMs are non-steroids, they are still performance enhancers and banned by certain organizations governing professional athletes. It’s your responsibility to perform due diligence to ensure compliance.

WADA’s (World Anti-Doping Agency) prohibited list states that SARMs have been prohibited by the World Anti-Doping Agency (WADA) since 2008. SARMs have the potential to make athletes misuse it for performance enhancement in sport because of the anabolic properties. In addition, it can stimulate androgen receptors in muscle and bone. You will find SARMs in the category of “other anabolic agents” under section Sl.2 of the WADA Prohibited List. Some examples of SARMs are Ostarine and Andarine.

At the moment, SARMs are not classified as a scheduled drug, neither are they classified as a food supplement. SARMs are not illegal. They are potentially new drug candidates. Therefore categorized for research.


Cicco-Ligandrol LGD4033 5mg is an oral Selective Androgen Receptor Modulator (SARM) research drug. They note is as a candidate for a possible new drug.


Non-steroidal SARMs act on specific androgen receptors in a number of key tissues found all over the human body. Worth mentioning is that you can find androgen receptors in the prostate, seminal vesicle, male and female genitalia, skin, testis, ovary, cartilage, sebaceous glands, hair follicles, sweat glands, cardiac muscle, smooth muscle, gastrointestinal vesicular cells, thyroid follicular cells, adrenal cortex, liver, pineal, and brain.

Ciccone Pharma SARMs is are research drugs. They administer it as a treatment for hypogonadism by increasing levels of the Natural Androgen Receptor (AR), ligands testosterone (T), and DHT.  Male hypogonadism is a condition where not enough testosterone is being produced. This is a condition that you can be born with, or it could develop as a result of an injury, old age or an infection. The effects of hypogonadism are muscle mass loss, depression, increase in body fat and low libido. Administering SARMs will reverse the effects of hypogonadism, but unlike other exogenous androgens, SARMs will not affect the prostate.

SARMs act as an antagonist to the androgenic organs like the prostate and bind directly to the receptors and are an agonist in anabolic tissues like muscle and bone.


Key SARMs benefits include: increased muscle mass, decreased fat mass and increased bone mass.

Phase I clinical trials of Ciccone Pharma SARMs measured an increase of l.5 kg of muscle mass in a 4-6 week trial period with no significant increase in body fat. They did not do these trials on healthy athletes who follow an eating regime that support muscle gain. They did the trials on people with muscle-wasting illnesses.

SARMs also activate AMPK, a mechanism involved in fat oxidation and lipolysis. Testosterone-derived compounds also increase muscle mass and decrease fat mass, but unlike these compounds, SARMs do not significantly suppress LH and FSH levels unless exceptionally high doses (3-4x the median effective dose) are administered. This further supports the notion that SARMs may be safer long-term than testosterone-derived steroidal compounds.

Androgens appear to increase periosteal bone formation in cortical bone whereas estrogen compounds decrease this formation. Androgens help to build the dense and compact outer layer of the bone which help support the skeleton, protect organs, store calcium, and provide levers for movement. Increase in bone formation and decreasing bone turnover suggests SARMs as a treatment for patients developing or already diagnosed with osteoporosis.


Regarding the increase of lean muscle mass, the strongest SARM developed to date is Cicco-Ligandrol LGD4033 5mg. It seems to greatly reduce muscle wasting caused by acute and chronic diseases and old age. its anabolic activity is not only pronounced in muscles but also in bones. Bone density increases dramatically. Noticeable decrease in body fat and an increase in strength.

Cicco-Ligandrol LGD4033 5mg has no androgenic side effects as from anabolic steroids (for example the prostate). It also has no adverse effects on the liver and kidneys and does not convert to estrogen. Because it does not convert to estrogen it does not affect the libido negatively. It increases sexual performance.

Cicco-Ligandrol LGD4033 5mg has a bigger affinity for binding with androgenic receptors in muscles.